Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ · Manufacturing · Pharmaceutical preparations
$516.56+$3.35 (+0.65%) on the dayAs of the close; data may be delayed.
MDGL price, last 12 months
Key stats
- Previous close
- $513.21
- Open
- $513.75
- Day range
- $511.31 – $523.96
- 52-week range
- $393.61 – $615.00
- Volume
- 118.6K
- Avg volume (20 days)
- 214.6K
- Market cap
- $11.9B
Performance
1W−2.8%
1M−4.1%
3M+0.8%
6M−0.4%
YTD−11.3%
1Y+21.0%
vs S&P 500, 1Y+4.2 pts
Technicals and fundamentals
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $11.9B